Aimmune Therapeutics, Inc. (AIMT) News

Aimmune Therapeutics, Inc. (AIMT)

Today's Latest Price: $34.49 USD

0.10 (-0.29%)

Updated Oct 12 12:00am

Add AIMT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter AIMT News Items

AIMT News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest AIMT News From Around the Web

Below are the latest news stories about Aimmune Therapeutics Inc that investors may wish to consider to help them evaluate AIMT as an investment opportunity.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics, Inc. - AIMT

NEW YORK , Sept. 18, 2020 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City , is investigating Aimmune Therapeutics, Inc. ("Aimmune" or the "Company") ( AIMT ) relating to the sale of the Company to Sociétés des Produits Nestlé, S.A. Under the terms of the agreement, Aimmune shareholders are anticipated to receive $34.50 per share for each share of Aimmune they own. … Full story available on

Benzinga | September 18, 2020

Merger Arbitrage Analysis And Spread Performance - September 13, 2020

This weekly column explains the reasons behind the movement in a selection of the largest U.S. cash merger arbitrage spreads from the past week as calculated by Merger Arbitrage Limited. We analyze the attractiveness and profitability of each spread going forward and indicate the trading position or action we have...

Mal Spink, CFA on Seeking Alpha | September 14, 2020

Development of Needle Free Alternatives for Treatment of Anaphylaxis Underway as Aquestive Therapeutics Launches Phase 1 Clinical Trial -

DUBLIN--(BUSINESS WIRE) published a new article on the allergy drugs industry "Allergy Drugs" Nestle has agreed to buy Aimmune Therapeutics Inc in a $2.6 billion deal. Nestle has built a large health science business focused on dietary management and the deal will add Aimmunes's Palforzia to its portfolio. Palforzia is the first FDA approved treatment to reduce the frequency and severity of allergic reactions to peanuts in children and teenagers. The drug is derived from

Business Wire | September 11, 2020

Aimmune Therapeutics: A Bargain For A Potential Blockbuster Therapy

Investment Thesis Earlier this year, Aimmune Therapeutics, Inc. (AIMT) unveiled Palforzia, the first and only FDA approved therapy to suppress the effects of peanut allergy. The lockdown measures hindered its market launch, and the company failed to realize sales to arrest the stock’s decline. Despite a rich portfolio of drugs...

Dulan Lokuwithana on Seeking Alpha | September 9, 2020

AIMMUNE INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of  Aimmune Therapeutics Inc. - AIMT

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of  Aimmune Therapeutics Inc. (NasdaqGS: AIMT) to Sociétés des Produits Nestlé, S.A. Under the terms of the proposed transaction, shareholders of Aimmune will receive only $34.50 in cash for each share of Aimmune that they own. KSF is seeking to determine whether this consideration and the process that led to i

Business Wire | September 4, 2020

AstraZeneca's Farxiga Data, And Other News: The Good, Bad And Ugly Of Biopharma

AstraZeneca reports positive data for Phase III Farxiga trial AstraZeneca (AZN) reported that Farxiga has shown robust decline in the risk of kidney failure, cardiovascular or renal death in patients suffering from chronic kidney disease. The data from the Phase III DAPA-CKD trial showed that Farxiga in combination with standard...

Avisol Capital Partners on Seeking Alpha | September 2, 2020 | WATCH | Nestlé secures peanut allergy treatment

Nestlé will pay $2 billion to buy the remaining stake in Aimmune Therapeutics, gaining full ownership of the first US-approved peanut allergy treatment.

News24 | September 1, 2020

60 Biggest Movers From Yesterday

Gainers Aimmune Therapeutics, Inc (NASDAQ: AIMT) shares jumped 171.6% to close at $34.22 on Monday after Nestle SA agreed to acquire the company at an …

Benzinga | September 1, 2020

Aimmune Therapeutics rallies on Nestle acquiring, Akcea cheers Ionis acquiring 24% remaining stake, ADiTx Therapeutics and Lipocine among major losers

Gainers: Aimmune Therapeutics (AIMT) +172%, Akcea Therapeutics (AKCA) +60%, Pro-Dex (PDEX) +16%, Kindred Biosciences (KIN) +14%, Neuronetics (STIM) +11%.Losers: ADiTx Therapeutics (ADTX) -11%, Lipocine (LPCN) -11%, Orchard Therapeutics (ORTX) -11%, CNS Pharmaceuticals (CNSP) -9%, Anchiano Therapeutics (ANCN) -8%....

Seeking Alpha | August 31, 2020

GTX, GME, GNW and AIMT among midday movers

Gainers: Aimmune Therapeutics (AIMT) +171%.Akcea Therapeutics (AKCA) +60%.Genworth Financial (GNW) +29%.Color Star Technology (HHT) +25%.GameStop (GME) +24%.Kindred Biosciences (KIN) +20%.Atomera Incorporated (ATOM) +18%.ChinaNet Online Holdings (CNET) +18%.AutoWeb (AUTO) +16%.Neuronetics (STIM) +17%.Losers: Shiloh Industries (SHLO) -63%. PEDEVCO (PED) -16%.Regis Corporation (RGS) -16%.Garrett Motion Inc. (GTX) -15%.VivoPower International PLC (VVPR) -15%.ADiTx Therapeutics, Inc. (ADTX)...

Seeking Alpha | August 31, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6058 seconds.